BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 3530439)

  • 21. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
    Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
    J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation.
    Buckley RH; Schiff SE; Sampson HA; Schiff RI; Markert ML; Knutsen AP; Hershfield MS; Huang AT; Mickey GH; Ward FE
    J Immunol; 1986 Apr; 136(7):2398-407. PubMed ID: 2869085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depletion of T cells from human bone marrow with monoclonal antibody CT-2 and complement.
    Trigg ME; Billing R; Sondel PM; Dickerman JD; Erickson C; Finlay JL; Bozdech M; Hong R; Padilla-Nash H; Terasaki P
    J Biol Response Mod; 1984 Aug; 3(4):406-12. PubMed ID: 6384432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional depletion of T cells by vincristine and methylprednisolone as an in vitro model for the prevention of graft versus host disease.
    Lanfranchi A; Andolina M; Tettoni K; Porta F; Locatelli F; De Manzini A; Candotti F; Albertini A
    Haematologica; 1992; 77(1):11-5. PubMed ID: 1398275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR; Taylor PA; Vallera DA
    J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Transplantation of allogeneic bone marrow treated in vitro with Campath-1 monoclonal antibody].
    Chapuis B; Helg C; Maurice P; Wyss M; Pipard G; Irlé C; Jeannet M
    Schweiz Med Wochenschr; 1985 Oct; 115(43):1521-2. PubMed ID: 3909387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
    Cobbold SP; Hale G; Clark MR; Waldmann H
    Prog Clin Biol Res; 1990; 333():139-51; discussion 152-4. PubMed ID: 2308978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depletion of T cells from bone marrow for allogeneic transplantation: method for treatment of bone marrow in bulk.
    Trigg ME; Peterson A; Erickson C; Bozdech M; Billing R; Sondel P; Finlay J; Surfus J; Stuiber M; Hong R
    Exp Hematol; 1986 Jan; 14(1):21-6. PubMed ID: 3080322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Graft-versus-host disease after marrow transplantation.
    Storb R
    Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation.
    Remberger M; Svahn BM; Hentschke P; Löfgren C; Ringdén O
    Bone Marrow Transplant; 1999 Oct; 24(8):823-30. PubMed ID: 10516691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
    Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
    Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T cell depletion.
    Bunin N; Aplenc R; Iannone R; Leahey A; Grupp S; Monos D; Pierson G
    Bone Marrow Transplant; 2005 Feb; 35(4):369-73. PubMed ID: 15640818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.